MYC and synovial sarcoma: In SS, chromosomal alterations resulting in the dysregulation of the MYC oncogene and IL-2 receptor signaling pathway, the activation of cytokine pathways, and the inhibition of P53 accounts for the increased cell proliferation and leukemic behavior observed in patients with this disease (3, 4).